减肥新药——盐酸西布曲明

被引:2
作者
沈灵佳
机构
[1] 湖北省医药工业研究院武汉
关键词
西布曲明; 代谢物; 大鼠; 单剂量; 耐受性; 代谢产物; 肥胖病; 肥胖症; 体重减轻; 新药;
D O I
暂无
中图分类号
R589.2 [脂肪代谢障碍];
学科分类号
摘要
<正> 肥胖(obesity)本身不是一种疾病,但肥胖症带来的健康问题却不容忽视。过分肥胖可引起或加重许多严重的疾病,如高血压、高血脂、缺血性心脏病、中风、糖尿病以及一些其它慢性疾病,且超重患者的死亡率大大高于正常人群。据估计,世界上肥胖症人数达到1亿以上,其中美国比例最高。随着生活水平的提高和生活习惯的改变,我国肥胖症患者的人数也在逐年增加,由此带来的心血管病和糖尿病等慢性致命性疾病的增加已引起人们警觉。
引用
收藏
页码:220 / 222
页数:3
相关论文
共 18 条
  • [1] Products in 1998. Scrip Magazine . 1999
  • [2] Sibutramine: a novel antiobesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Heal,DJ,Aspley,S,Prow,MR,Jackson,HC,Martin,KF,Cheetham,SC. International Journal of Obesity and Related Metabolic Disorders . 1998
  • [3] Current concepts in the pharmacological management of obesity. Carek PJ,Dickerson LM. Drugi . 1999
  • [4] Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Jackson HC,Needham AM,Hutchins LJ,et al. British Journal of Pharmacology . 1997
  • [5] Sibutramine: a review of its contribution to the management of obesity. McNeely W,Goa KL. Drugs . 1998
  • [6] Drugs of the Future . 1988
  • [7] Ger Pat 3212682 . 1982
  • [8] NAS in 1998. Scrip Magazine . 1999
  • [9] Obesity treatment. Wildiing J. British Medical Journal . 1997
  • [10] Unlisted Drugs . 1999